Sector Expert: Keith Markey

Griffin Securities

Image: Keith Markey

Keith Markey has been an equities analyst for more than 25 years, specializing in the biotechnology, pharmaceutical, medical device and research tools sectors. He is currently the science director for Griffin Securities Inc., an investment bank where he follows emerging healthcare companies with novel technologies. He also works with privately owned companies, helping them restructure their operations, license products under development or near commercialization and raise funds from venture capital and high net-worth investors. In addition, Markey serves on the board of directors of DS Healthcare Group, which specializes in products that address hair loss. Previously, he held various managerial positions in the Research Department of Value Line Inc., publisher of the Value Line Investment Survey and Value Line Select. Markey began his career as a biochemist, working in the fields of endocrinology and neuroscience at New York University Medical School and Weill Cornell Medical College. His research, which involved several international collaborations and resulted in more than 30 scientific publications, contributed to the understanding of regulatory biochemistry of the nervous system and stem cell plasticity. Markey received his doctorate in neurochemistry from the University of Connecticut and a master's degree in business administration and finance from the Leonard N. Stern School of Business at New York University.



Recent Quotes

"Based on RXI's new checkpoint inhibitors and the potential for multiple partnering deals, we are maintaining our Buy recommendation."

— Keith Markey, Griffin Securities (5/4/17)
more >

"RXII's acquisition of MirImmune is an attractive opportunity."

— Keith Markey, Griffin Securities (10/12/16)
more >

— Keith Markey, Griffin Securities (8/22/16)
more >

"RXII is focused on garnering a higher valuation of its technologies."

— Keith Markey, Griffin Securities (8/14/15)
more >

"RXII raised $9.3M, enough funds to support operations through 2017."

— Keith Markey, Griffin Securities (5/29/15)
more >

"RXII's R&D pipeline has multibillion dollar sales potential."

— Keith Markey, Griffin Securities (4/1/15)
more >

"SNGX has a diversified portfolio of innovative products."

The Life Sciences Report Interview with Keith Markey (10/9/14)
more >

"RXII's molecules are designed specifically to facilitate the uptake of their therapeutic payload."

The Life Sciences Report Interview with Keith Markey (10/8/14)
more >



Due to permission requirements, not all quotes are shown.